KYNBHIGH SIGNALOPERATIONAL10-K

KYNB underwent a major corporate transformation, rebranding from FibroGen to Kyntra Bio while divesting international operations and dramatically reducing scale of operations.

The company completed a strategic pivot that fundamentally changed its business model, shifting from a global pharmaceutical company to a smaller, more focused entity. The transformation involved selling FibroGen International to AstraZeneca and repositioning as Kyntra Bio with significantly reduced operational complexity and financial obligations.

Comparing 2026-03-16 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reflect a complete business transformation with net income swinging dramatically positive to $183.5M (likely driven by divestiture gains) despite revenue collapsing 78% to $6.4M. The company emerged much smaller but financially healthier, with R&D expenses cut 75% to $23.5M, operating cash flow burn reduced 97% to just $4.8M, and total liabilities slashed 71% to $115.1M. While stockholders equity remains negative at -$30.0M, it improved substantially from -$225.6M, indicating the restructuring significantly strengthened the balance sheet despite the dramatic reduction in business scale.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+485.6%
-$47.6M→$183.5M

Net income grew 485.6% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+96.5%
-$138.0M→-$4.8M

Operating cash flow surged 96.5% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+86.7%
-$225.6M→-$30.0M

Equity base grew 86.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-85.7%
$266K→$38K

Capex reduced 85.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
-78.3%
$29.6M→$6.4M

Revenue declined 78.3% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
-78.1%
$133.3M→$29.2M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-75.4%
$95.7M→$23.5M

R&D spending cut 75.4% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
-71.1%
$398.2M→$115.1M

Liabilities reduced 71.1% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+69.5%
-$150.4M→-$45.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
-55.1%
$481K→$216K

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-17
ADDED
2 RISK FACTOR SU MMARY The success of Kyntra Bio will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following: Risks Related to the Development and Commercialization of Our Product Candidates We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our PET (as defined below) imaging agent FG-3180).
The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.
and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
International Risks Within the next year, we may face costs from the wind-up of the Cayman Subsidiary (as defined below), and may not receive some of the AZ Holdbacks (as defined below) related to the sale of FibroGen International and its subsidiaries.
and China relations, as well as relations with other countries, and/or regulations may adversely impact our business.
+7 more — sign up free →
REMOVED
2 RISK FACTOR SU MMARY The success of FibroGen will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following: Risks Related to the Development and Commercialization of Our Product Candidates We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our positron emission tomography ( PET ) imaging agent FG-3180).
The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the United States, and we may encounter significant problems in securing and defending our intellectual property rights outside the United States.
We are subject to stringent and evolving United States and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
Risks Related to Our International Operations If we are unable to consummate the sale of FibroGen International to AstraZeneca Treasury Limited, the trading price of our common stock and our business may be harmed.
We have established operations in China and there are a number of risks associated with international operations could materially and adversely affect our business.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →